Three years of continuous treatment with Lecanemab (Leqembi) has shown to reduce cognitive decline by -0.95 on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale, with over 50% of patients showing cognitive function improvements.
Open the full topic